Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a major breakthrough with the Twiist insulin pump and the recent ADA/EASD T2D guidelines.
News|Videos|September 1, 2026
5 Nephrology Headlines You Missed in August 2026
Author(s)Alex Hillenbrand
Fact checked by: Chelsie Derman
A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.
Advertisement
Advertisement
August 2026 brought a wave of practice-shifting nephrology news, headlined by the first joint
Related to this article
George Washko, MD, discusses a late-breaking OBERON/TITANIA analysis showing tozorakimab reduces segmental mucus plug scores in COPD.
Advanced practice providers described how documentation, specialty pharmacy support, and payer requirements shape biologic selection and timing.
Participants said payer criteria and patient goals often outweigh mechanism when choosing biologics, and that shared decision-making is harder in COPD.
A single Revita procedure preserved about 80% of tirzepatide-induced weight loss at six months in the REMAIN-1 pivotal cohort.
AASLD’s first Expert Practice Opinion adds EUS-guided biopsy and sets no INR or platelet thresholds.
Real-world data from ACG 2026 show elafibranor lowered ALP in patients with PBC who switched from obeticholic acid and in those new to second-line therapy.
Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.
Advertisement
Advertisement